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Parkinson’s disease (PD)is aprogressive neurodegenerative movement disordercharacterized bythe selective loss of dopaminergic
neurons and the presence of Lewy bodies. The pathogenesis of PD is not fully understood, but it appears to involve both genetic
susceptibility and environmental factors. Treatment for PD that prevents neuronal death progression in the dopaminergic system
and abnormal protein deposition in the brain is not yet available. Recently, mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene have been identiﬁed to cause autosomal-dominant late-onset PD and contribute to sporadic PD. Here, we review the
recent models for LRRK2-linked Parkinsonism and their utility in studying LRRK2 neurobiology, pathogenesis, and potential
therapeutics.
1.Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder with movement, cognitive, and emo-
tional dysfunction, aﬀecting 2% of the population over the
age of 60 years [1]. PD is characterized by tremors, rigidity,
bradykinesia/akinesia,andposturalinstabilityresultingfrom
the loss of dopamine neurons in the substantia nigra and
other regions of the brain [2–5]. The pathological hallmark
ofPDisthepresenceofproteinaceouscytoplasmicinclusions
termed Lewy bodies [5, 6]. PD is similar to other neurode-
generative diseases in that it presents with neuronal cell
death and protein aggregation, though the relation between
them is uncertain [6, 7]. The pathogenesis of PD remains
incompletely understood, but it appears to involve both
genetic susceptibility and environmental factors. Treatment
for PD that prevents neuronal death progression in the
dopaminergic system and abnormal protein deposition in
the brain is not yet available.
Recently, mutations in the LRRK2 gene have been
identiﬁed to cause autosomal dominant PD and contribute
to sporadic PD [8–10]. To date, more than 50 variants
including at least 16 disease-causing mutations have been
reported [11–22]. This paper highlights the recent models
for LRRK2-linked Parkinsonism and their utility in studying
LRRK2 neurobiology, pathogenesis, and potential therapeu-
tics. For other aspects of LRRK2 please refer to several recent
excellent review papers [23–26]. Due to the length of this
review, we apologize that we did not include all LRRK2
publications.
2. LRRK2 Geneand Protein
The LRRK2 gene spans a genomic region of 144Kb, with
51 exons encoding 2527 amino acids. The LRRK2 mRNA is
expressed throughout the brain and other organs [9]; in situ
hybridization in mice reveals that expression predominates
within regions of the basal ganglia, which are associated with
motor dysfunction in PD, and within nonmotor areas such
as the hippocampus [27–31]. The LRRK2 gene is conserved
across species from invertebrates to human. Caenorhabditis
elegans and Drosophila melanogaster each have only one
LRRK2 ortholog [9].
The LRRK2 protein contains several predicted domains
(Figure 1)includingRoc(Rasincomplexproteins,belonging
to the Ras/GTPase family), COR (C terminal of Roc), LRR,
a leucine-rich repeat, consisting of twelve repetitions of
a 22–28 amino acid motif, MAPKKK, a protein kinase
catalytic domain which may be involved in serine/threonine
phosphorylation, a WD40 domain and ankyrin repeats.
The LRR and WD40 domains may be involved in protein-
protein interactions [32]. The LRRK2 protein is expressed
in all tissues examined, although at low levels. In the brain,
LRRK2 is expressed in neurons, astrocytes, and microglia.2 Parkinson’s Disease
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Figure 1: LRRK2 domain structure and PD-linked point mutations. The predicted domain boundaries are indicated by the residue numbers
beneath. The position of the putatively pathogenic amino acid substitutions are shown in purple. Substitutions segregating with PD are
shown in green. The kinase null and no-GTP binding alterations are shown in red.
Recent studies have detected LRRK2 in speciﬁc brain regions
including the cortex, striatum, hippocampus, cerebellum
and in dopaminergic neurons of the substantia nigra [30,
31, 33, 34]. However, the expression levels of LRRK2 in the
dopaminergic neurons of the SNpc are very low. LRRK2
protein can be detected in Lewy neurites [35] and in Lewy
bodies of sporadic PD [36]. In the subcellular level, it
was found mainly in the cytoplasm and associated with
lipid rafts, lysosomes, endosomes, mitochondria, and Golgi
transport vesicles [9, 30, 33, 34, 37–39]. Several studies show
that LRRK2 is enriched at the membrane of cells [30, 31, 40,
41] and that the membrane-associated fraction of LRRK2
may display greater kinase and GTP-binding activities than
cytosolic LRRK2 [41]. Another study shows the recruitment
of LRRK2 to the endosomal-autophagic pathway suggesting
the functional involvement of LRRK2 in this pathway
[42, 43].
Patients with LRRK2 mutations typically have a relatively
late onset of PD with asymmetric rest tremor, bradykinesia,
rigidity, and a good response to L-DOPA treatment [9,
44]. The pathological heterogeneity of aﬀected individuals
examined ranges from pure nigral degeneration without
Lewy bodies to nigral degeneration associated with Lewy
bodies, widespread Lewy bodies consistent with diﬀuse Lewy
body disease, or neuroﬁbrillary tau-positive tangles [8, 9, 45,
46]. Point mutations have been identiﬁed in almost all of the
predicted domains of LRRK2 (Figure 1)[ 1, 21, 22, 47–49].
The most common mutation, G2019S, contributes to 5-6%
of autosomal-dominant PD [50, 51] and 1-2% of sporadic
PD [52]. The distribution of mutations across several diﬀer-
entLRRK2domains,thelackofdeletionsortruncations,and
the dominant pattern of inheritance, are consistent with a
gain-of-function mechanism for LRRK2-associated PD.
T h en o r m a lf u n c t i o no fL R R K 2i ss t i l lu n c l e a r .L o s s -
of-function studies indicate that the Drosophila LRRK2
homologous protein (CG5483) is critical for the integrity
of dopaminergic neurons in the ﬂy [53]a n dZ e b r a ﬁ s h
LRRK2 homology is important for neuronal development
[54]. Suppression of LRRK2 with siRNAs or a dominant
inhibitory allele leads to increased neurite process length and
complexity [55]. Based on the multidomain structure and
various identiﬁed LRRK2 mutations, LRRK2 is predicted to
serve as an upstream central integrator of multiple signaling
pathways that are crucial for proper neuronal function-
ing. The presence of LRR and WD40 (protein interaction
domains) and Roc and MAPKKK (enzymatic domains)
within LRRK2 suggests that this protein may serve as a
scaﬀoldfortheassemblyofamultiproteinsignalingcomplex.
LRRK2 associates with various protein partners that are
involved in several cellular pathways including chaperone
machinery, cytoskeleton arrangement, protein translational
machinery, synaptic vesicle endocytosis, the MAPK sig-
naling cascades, ubiquitin/autophage protein degradation
pathways, and other unidentiﬁed processes [23].
3.In Vitro Models andLRRK2 Biology
Studies using in vitro models (Table 1) reveal that LRRK2
is a kinase and a GTPase and identify various interaction
partners, suggesting that LRRK2 may play important roles
in protein aggregation and neuronal degeneration.
3.1. LRRK2 Kinase Activity. In vitro studies demonstrate that
LRRK2 is predominately a serine/threonine protein kinase,
which can phosphorylate itself and a generic substrate,
myelin basic protein (MBP) [39, 55–60]. A LRRK2 variant
with three potential sites of autophosphorylation altered to
alanines (T2031A, S2032A and T2035A), does not display
autophosphorylation activity and cannot phosphorylate the
generic substrate, MBP [61, 62]. Further in vitro studies
demonstrate that S2031 and T2032 are the critical residues
required for LRRK2 autophosphorylation, and T2035 is
important for catalytic activity, but does not serve as a
phosphate acceptor [58]. Additional studies show that
dimeric LRRK2 undergoes intramolecular autophosphory-
lation and that an intact C-terminus is required for kinase
activity [61]. One recent report shows that T1343 also is an
autophosphorylation site [63]. Moreover, S910 and S935 are
also potential phosphorylation sites that may be involved in
14-3-3 proteins binding with LRRK2 [64–66]Parkinson’s Disease 3
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Figure 2: UAS/GAL4 system and ﬂy brain dopaminergic neurons. A. Diagram of GAL4/UAS system to illustrate that tissue-speciﬁc expression
of GAL4 leads to transcriptional activation of LRRK2. B. Diagram of DA neuron clusters in the medial and lateral areas of the adult ﬂy brain
as in previous publications [34, 67]. Five clusters: PPM1 (unpaired), PPM2 (paired), PPM3 (paired; protocerebral posterior medial), and
PPL1 and PPL2 (paired; protocerebral posterolateral) on the posterior side. (Center) Two DA clusters: PAL (protocerebral anterolateral) and
PAM (paired anterolateral medial) on the anterior side. C. Images of whole-mount-immunostaining of dopaminergic neurons in a adult ﬂy
brain using anti-TH antibodies followed by green ﬂuorescent-conjugated second antibody detection.
Several pathogenic mutations of LRRK2 in PD have been
found within the protein kinase domain active segment
(e.g., G2019S), suggesting that these mutations may cause
pathology through altering the kinase activity of LRRK2
[23]. The results from the most common mutation G2019S
support this notion to increase LRRK2 kinase activity in
assays to measure autophosphorylation or phosphorylation
of generic substrates [39, 55–59]. However, controversy
remains regarding whether other PD mutations alter LRRK2
kinase activity. For example, several studies demonstrated
that the I1122V, R1441C, R1441G, R1514Q, Y1699C, and
I2020T familial PD linked mutations of LRRK2 increased
kinase activity [35, 37, 57, 67, 68]. Additionally, other
mutations either did not inﬂuence or inhibit kinase activity
[59, 60, 69]. Currently, LRRK2 kinase assays use in vitro
autophosphorylation or phosphorylation of generic sub-
strate or a phosphopeptide. Accordingly, the kinase activity
results of some mutants vary among various laboratories,
in part due to lack of sensitivity in the kinase assay of
choice and various expression constructs. Identifying a
physiologicsubstrateofLRRK2andresolvingthequestionof
whether pathogenic mutations aﬀect phosphorylation of this
substrate is critically important to determine the mechanism
by which LRRK2 induces PD see Figure 2.
To date, the physiological substrate(s) of LRRK2 remains
unclear [23]. A search for proteins that are phosphorylated
by the PD-linked mutant LRRK2-G2019S using rat brain
extracts reveals that moesin is a substrate [59]. Moesin is
a protein that anchors the actin cytoskeleton to the plasma
membrane. Denatured moesin is eﬃciently phosphorylated
by LRRK2 at Thr558, the residue previously identiﬁed as
an in vivo phosphorylation site that regulates the ability of
moesin to bind actin. LRRK2 also phosphorylates ezrin and
radixin, which are involved in moesin binding actin [59].
Collapsing response mediator protein-2 (CRMP-2) has also
been identiﬁed as a weak LRRK2 substrate, which is involved
in the regulation of growth cones, microtubule dynamics
and neurogenesis [70]. Recent reports also show that 4E-
BP [71] and mitogen-activated protein kinase can also be
phosphorylated by LRRK2 [72–74]. Additional studies are
required to establish the physiological signiﬁcance of these
proteins as LRRK2 substrates.
3.2. LRRK2 GTP Binding and GTPase Activity. LRRK2 is
a member of the recently deﬁned ROCO family [75]a n d
harbors a GTP-binding regulatory domain (ROC-COR) [76,
77]. LRRK2 is a GTP/GDP-binding protein, as measured by
speciﬁc binding to GTP-agarose and radio-labeled GTP [57,
60, 76]. Both wild-type and PD-linked mutant LRRK2 bind
to GTP and GDP. LRRK2-K1347A, which bears a mutation
that alters the predicted GTP-binding site, does not appre-
ciably bind to GTP and reduces kinase activity. This ﬁnding
is further conﬁrmed by the recent report showing that the
crystal structure of the LRRK2 ROC domain in complex
with GDP-Mg (2+) at 2.0-A resolution [78]. The crystal
structure displays a dimer of the ROC domain. Two PD-
associated pathogenic residues, R1441 and I1371, are located
at the interface of two monomers that may alter the ROC
dimerization and regulate LRRK2 GTPase and/or kinase
activity. LaVoie’s recent study further suggests that LRRK2
dimerization is associated with membrane binding and
increased GTPase activity [41]. Familial-linked mutations in4 Parkinson’s Disease
Table 1: LRRK2 in vitro cell models.
Genes Cell type Toxicity Protein
aggregation
Kinase
activity
GTPase
activity References
WT, R1441C, Y1699C,
G2019S
HEK293T
SH-SY5Y
Primary
neurons
+N DN D N D [ 79]
WT, I2020T HEK293 ND ND + ND [38]
WT, G2019S, R1441C HEK293
SH-SY5Y ND ND + ND [39]
WT, G2019S, I2020T Primary
neuron ++ + N D [ 55]
WT, R1441C, Y1699C,
G2019S SH-SY5Y + + + ND [56]
WT, G2019S, G2019S-
K1906A, G2019S-
D1994N, G2019S-
DY2017-2018AL, WT-
K1347A, G2019S-
K1347A
HEK-293
SH-SY5Y
Primary
neuron
+N D + +[ 57]
WT, K1906M, G2019S,
R1441C, R1441G,
I1371V, I1122V,
R1514Q, Y1699C,
G2385R, I2012T, I2020T
HEK293FT
SH-SY5Y
Primary
neuron
+N D + +[ 60]
WT, G2019S, A2016T,
WT/A2016T,
G2019S/A2016T,
R1441C, Y1699C
HEK-293
Swiss-3T3
Human lym-
phoblastoid
cells
ND ND + ND [80]
WT, T1343G, K1906M,
T2035A, R1398Q
HEK-293
Neuro-2a ND ND − ND [76]
WT, R1441C/G, T1398N HEK-293T ND ND ND + [67]
WT, G2019S
HEK-293
Primary
neuron
ND ND + ND [81]
WT: wild type; ND: not determined.
LRRK2withintheROCandCORdomains(I1371V,R1441C,
R1441G, and Y1699C) appear to increase GTP-binding as
measured by binding to GTP-agarose, whereas mutations
outside these domains did not aﬀect GTP binding compared
with wild-type LRRK2 [60]. However, other studies have
shown that R1441C mutation do not increase GTP binding
[67, 69].
The ROC domain of LRRK2 shares sequence homology
with all ﬁve subfamilies of the Ras-related small GTPase
super family (Ras, Rho, Rab, Sar/Arf and Ran) and contains
conserved motifs for GTPase activity. Three independent
groups have demonstrated that LRRK2 has intrinsic GTPase
activity and undergoes intrinsic GTP hydrolysis [67–69, 82,
83]. The puriﬁed full-length LRRK2 has only weak GTPase
activity, suggesting that if it is active in the cell it may require
accessory proteins. Notably, the ROC domain of LRRK2 is
suﬃcient for its intrinsic GTPase activity. LRRK2 binds and
hydrolyzesGTPsimilarlytootherRas-relatedsmallGTPases.
Based on in vitro assays, R1441C/G and Y1699C PD-linked
mutations appear to decrease in the rate of GTP hydrolysis
compared to the wild-type LRRK2, suggesting that these
mutants spend more time in the activated GTP-bound state
[69, 78, 84].
Several studies have demonstrated that GTPase domain
activity may regulate LRRK2 kinase activity [57, 58, 67,
82] since GTP binding stimulating LRRK2 kinase activity
[58, 67] although there is still some evidence against the
GTP binding activation model [85]. It is hypothesized that
LRRK2, like other Ras-related GTPases, may serve as a
molecular switch to regulate diverse cellular functions by
cycling between GTP-bound (active) and GDP-bound (inac-
tive) conformations. Based on the putative dimeric structure
ofLRRK2,itispredictedthatthedimericROCorROC-COR
domains act as binary switches to regulate kinase activation
[78, 84]. In this model, at the GTP-bound conformation,
the dimerization of ROC or ROC-COR domains further
induces self-association of the kinase domains, thus allow-
ing for autophosphorylation and subsequent activation ofParkinson’s Disease 5
downstreamkinaseactivity[61,78,84].LRRK2mayregulate
itsownactivity,aswellasperhapsfulﬁllingasignalingroleby
regulating other proteins in the cell [41, 61, 86–88]. Multiple
reports have shown that the kinase domain of wild-type
LRRK2 phosphorylates several sequences within the GTP-
binding ROC domain [61, 63, 89, 90], suggesting that the
kinase domain may also regulate overall LRRK2 function.
The PD-linked mutations do not identically display the
same kinase or GTP domain activities, suggesting that there
may be some interesting mechanistic diﬀerences between
diﬀerent mutations in the same domain, however the caveat
that these observations could also be due to methodological
diﬀerencesbetweenassays[91].Nevertheless,mutationsmay
prompt the protein to enter a GTP-bound state or slow the
protein’s return to the GDP-bound state.
3.3. Mutant LRRK2 Induces Toxicity. Patients with LRRK2
mutations exhibit neuronal degeneration in the brain [8, 9,
45–47]. PD-associated mutations of LRRK2 induce cell toxi-
city in multiple cell lines and rodent primary neurons with
reduction of cell viability ranging from 10–40% (Table 1).
Expression of mutant LRRK2 variants (I1122V, R1441C,
Y1699C, G2019S, and I2020T) strikingly decreases neuronal
cell viability by 2–5-folds. However, overexpression of wild
type LRRK2 does not signiﬁcantly decrease cell viability [55–
58, 60, 79, 92].
Mutant LRRK2-mediated cell toxicity appears to involve
apoptotic mechanisms as measured by TUNEL staining and
caspaseactivation[57,58,79].Themitochondria-dependent
apoptotic pathway, in which cytochrome c is released and
caspase-3 is activated, is thought to mediate mutant LRRK2
toxicity in neuronal cells. This seems to be dependent
on Apaf1, a scaﬀold protein participating in apoptosome
formation [83]. Another study has also shown that LRRK2
interacts with the death adaptor Fas-associated protein
at the death domain (FADD), which may play a role in
apoptotic neuronal death [93]. Since kinase activity is a
critical component of LRRK2, signiﬁcant eﬀorts have been
made to determine whether kinase activity is responsible
for LRRK2 toxicity. Abolishing LRRK2 kinase activity
diminishes the toxicity of all PD mutants tested in cell
culture [56, 57]. Genetic alterations of LRRK2 with D1994N
(a predicted proton acceptor) abolishes the predicted active
site, K1906A (a ATP binding site) abolishes a putative ATP-
binding site, and/or DY2017-2018AL altering the predicted
DYG kinase active conserve motif signiﬁcantly reduces
LRRK2 kinase activity. Importantly, these constructs reduce
mutant LRRK2-induced neuronal degeneration [56, 57].
Additionally, one study has shown that overexpression of
the kinase domain, the ROC-COR-kinase fragment or the
ROC-COR-kinase-WD40 fragments containing G2019S and
R1441C mutations can reduce cell viability [94]. A recent
report further supports this notion that inhibitors of Raf
kinase GW5074, sorafenib and Raf inhibitor IV inhibit
LRRK2 autophosphorylation and MBP phosphorylation
result in reducing mutant LRRK2 toxicity [95].
R1441C and Y1699C mutants are associated with
reduced LRRK2 GTPase activity [68, 69, 82, 83] suggesting
that GTPase activity may contribute to LRRK2 toxicity.
In addition, the K1347A alteration abolishes GTP binding
and reduces kinase activity thereby reducing the mutant
LRRK2-induced neuronal toxicity in cell culture [57, 60]. A
recent study shows that the cytotoxic eﬀect of ROC-ROC-
kinase fragment in yeast was increased in a GTPase dead
background or after the induction of R1441C mutation,
which reduced GTPase activity [83]. This toxicity can be
reduced by introduction of GTPase stimulating alterations
(T1343G/R1398Q or R1398L). However, in cell culture, only
the augmentation of the toxicity eﬀect caused by ROC-
ROC-kinase fragment can be replicated [83]. Thus, the
contribution of GTPase domain activity in LRRK2 toxicity
still warrants further investigation.
Recent studies have also shown that deletion of the LRR
and WD40 domains can rescue G2019S and/or R1441C-
LRRK2-induced toxicity [92, 96], likely via kinase activity
as the deletion of the WD40 domain or even shorter C-
terminal sequences renders LRRK2 kinase inactive [59, 96].
Given that the LRR and WD40 are putative protein-protein
interaction domains, it is suggested that LRRK2 protein
interactions may also contribute to its toxicity. However,
this needs further study. Several pathogenic mutations
(I1122V, R1441C, Y1699C, G2019S, and I2020T) increase
the tendency of LRRK2 to form inclusion bodies [33, 56]
suggesting that LRRK2 kinase activity may also contribute to
protein aggregation [56, 79]. Together, these ﬁndings suggest
that LRRK2 protein kinase activity plays an important role
in both neuronal degeneration and protein aggregation, but
thecellularpathwaysunderlyingthesefunctionsneedfurther
study.
3.4. LRRK2 Interaction Partners and Potential Cellular Path-
ways. There is a growing number of LRRK2 interaction
partners that are identiﬁed and involved in several cel-
lular pathways including chaperone machinery, cytoskele-
ton arrangement, protein translational machinery, synaptic
vesicle endocytosis, the MAPK signaling cascades, ubiq-
uitin/autophage protein degradation pathways, and other
unidentiﬁed processes (Table 2).
LRRK2 interacts with proteins involved in chaperon
pathways including Hsp90, Hsp90//p50cdc37, HSp60, Hsp
70, and the c-terminal Hsp70 interacting protein (CHIP)
[38, 81, 88, 97–99]. The Hsp60 interacts with recombinant
human LRRK2 kinase domain in E. coli, and Hsp90/p50cdc37
interacts with full-length LRRK2 in mammalian cells [38,
58]. These chaperone proteins may help to maintain the
proper folding of LRRK2. The HSP90/p50cdc37 chaperone
complex binds to LRRK2 and may assist with the activa-
tion of other protein kinases [38]. In these studies, the
Hsp90/p50cdc37 proteins do not serve as substrates but
rather associate as chaperones assisting in proper folding and
activation of the kinase. It has been shown that inhibition of
Hsp90disruptstheassociationofthischaperonewithLRRK2
leading to proteasomal degradation of LRRK2, suggesting
that Hsp90 inhibitors may be useful therapeutically to
limit mutant LRRK2-mediated toxicity in neurons [81,
98]. CHIP binds ubiquitinates and promotes the ubiquitin
proteasomal degradation of LRRK2 [98]. Overexpression
of CHIP protects against mutant LRRK2-induced toxicity6 Parkinson’s Disease
Table 2: LRRK2 potential interaction proteins.
Pathway LRRK2 fragment Link with LRRK2 Method References
Apoptosis Full length FADD Co-IP
(HEK293T cells, mouse brain) [93]
Full length TRADD, RIP1 Co-IP
(HEK293T cells) [93]
Synaptic vesicle
endocytosis
Full length
LRR Rab5b YTH, pulldown,
Co-IP [111]
MAPK signaling
Full length,
COR,
Kinase domain
MKK3 Co-IP
(HEK293T cells) [72, 73]
Full length MKK4 Co-IP
(HEK293T cells) [72]
Full length,
COR,
Kinase domain
MKK6 Co-IP
(HEK293T cells), C. elegans [72, 73]
Full length,
COR,
Kinase domain
MKK7 Co-IP
(HEK293T cells) [72, 73]
Full length JIP1–3 Co-IP
(HEK293T cells) [74]
Full length JIP4 Co-IP
(HEK293T cells) [74]
Chaperone
machinery
Full length,
Kinase domain,
N-term
Hsp90
Co-IP
(HEK293T cells, mouse brain),
YTH
[81, 88, 97–99]
Full length,
Kinase domain, p50CDC37 Co-IP
(HEK293T cells, mouse brain) [38, 81]
Full length,
ROC, N-term CHIP
Co-IP
(HEK293T cells, mouse brain),
YTH
[98, 99]
cytoskeleton
Full length,
ROC a-tubulin pulldown [102]
Full length,
ROC b-tubulin
Co-IP
(HEK293T cells, mouse brain),
pulldown
[102, 105]
Full length EF1A
Co-puriﬁcation (insect cells),
Co-IP
(HEK293T cells)
[113]
—m o e s i n in vitro, in vivo [59, 101]
Full length,
ROC-COR DVL1/2/3 YTH, Co-IP
(HEK293T cells) [109]
Full length Sgg/GSK3b Drosophila [114]
Full length Actin cytoskeleton
proteins
QUICK,
Co-IP (NIH3T3 cells) [115]
Protein translation — 4E-BP in vitro, Drosophila [71, 116]
PD related proteins
and others
Full length, COR Parkin
Co-IP
(HEK293T cells, SH-SY5Y cells,
primary neurons),
[79]
Full length 14-3-3 isoforms
Co-IP
(HEK293T cells, Swiss 3T3 cells,
mouse brain, kidney, spleen)
[64–66, 80]
FADD: Fas-associated protein with death domain; TRADD: tumor necrosis factor receptor type 1-associated death domain protein; LRR: leucine-rich repeat;
YTH: yeast two-hybrid; ROC: Ras of complex protein; COR: C-terminal of ROC; MKK: mitogen activated protein kinase kinase; JIP: JNK interacting protein;
Hsp: Heat shock protein; CHIP: C-terminus of Hsp70 interacting protein; EF1A: elongation factor 1α; DVL: dishevelled family of proteins; Sgg: glycogen
synthase kinase 3β homolog Shaggy; QUICK: quantitative immunoprecipitation combined with knockdown.Parkinson’s Disease 7
whereas knockdown of CHIP exacerbates toxicity mediated
by mutant LRRK2 via reducing degradation of LRRK2
proteins.
LRRK2 associates with various cytoskeleton proteins
including alpha/beta-tublin, F-actin, moesin-related ezrin-
radixin-moesin (ERM) family members, and the dishev-
elled family proteins [100], suggesting that LRRK2 may
play a critical role in the regulation of microtubule and
actin dynamics. LRRK2 associated with actin dynamics is
evidenced by the following studies. MacLeod et al. ﬁrst
associated LRRK2 with the maintenance of neuronal process
[55] and demonstrated that the neurons expressing the
G2019S mutation but not wtLRRK2 had shorter neurites.
Suppression of LRRK2 expression by shRNAs led to an
increase in neurite length. Moreover expression of G2019S
mutation led to tau-positive inclusions, which also colocal-
ized with tau in these inclusions [55]. Biochemical studies
show that LRRK2 phosphorylates denatured moesin and
associates with other actin-binding ERM proteins: ezrin
and radixin [59]. Further studies indicate that LRRK2 may
connect with actin dynamics through phosphorylation of
ERM proteins [101]. In developing LRRK2 G2019S neurons,
the numbers of pERM and F-actin enriched ﬁlopodia were
signiﬁcantly increased, which correlates with the retardation
of neurite outgrowth in these neurons. Conversely, the
levels of pERM and F-actin within the ﬁlopodia of LRRK2
knockout neurons were signiﬁcantly decreased and neurite
outgrowth was promoted. These observations suggest a
physiological link between LRRK2 and pERM in neuron
development and neurite outgrowth [100].
Increasing evidence links LRRK2 with microtubule
dynamics. For instance, LRRK2 colocalizes [38, 102]a n d
interacts with tubulin through the LRRK2 ROC domain
[102, 103]. LRRK2 phosphorylates β-tubulin at Thr107
in mouse brain, and this phosphorylation is signiﬁcantly
enhanced by G2019S mutation [104]. In vitro studies shows
that tubulin phosphorylation by LRRK2 enhances micro-
tubule stability in the presence of microtubule-associated
proteins [105]. Moreover, levels of soluble β-tubulin are
dramatically decreased in brains of LRRK2 expression mice
[103, 106] and are signiﬁcantly increased in the brains of
LRRK2 KO mice [105]. The maintenance of microtubule
dynamics is critical for neuronal development, axonal traf-
ﬁcking as well as synaptic formation and maintenance. The
G2019S-enhanced tubulin phosphorylation may thus result
in deregulation of microtubule dynamics that may in turn
interfere with proper neuronal function [105]. Microtubules
and microtubule-axonal transport has been reported to play
a critical role in maintaining Golgi structure and integrity
[107, 108]. Increased fragmentation of the Golgi apparatus
was reported in transgenic mice overexpressing LRRK2,
and this strongly suggests that the enhancement of tubulin
polymerization aﬀects the organization of microtubule in
neuronsleadingtoGolgidisruption[103].Otherstudiesalso
show that LRRK2 interacts with the dishevelled family of
phosphoproteins (DVL1-3) and Rab5b suggesting that the
interactions may play an important role in axon guidance
and maintaining synaptic function [109, 110] by modulating
the endocytosis of synaptic vesicles, further supporting a role
for LRRK2 in traﬃcking [111]. Further investigation still
remains to determine whether LRRK2 kinase and GTPase
activities are involved in regulation of microtubule and actin
dynamics in neuron development, neurite outgrowth and
traﬃcking.
LRRK2 associates with proteins in other kinase cascades.
LRRK2 kinase domain shares homology with MLKs and
RIPKs, which are involved in signaling events in response
to cellular stress insults. Similar to MLKs, LRRK2 has been
shown to bind MKK3, 6 and 7 and to phosphorylate
MKK3, 4, 6 and 7 [72, 73]. LRRK2 also interacts with the
JNK-interacting proteins (JIPs) 1–4 which are scaﬀolding
proteins that bring together MKKs and MAPKs activating
the downstream kinases, JNK and p38 [74]. However, it is
still unclear whether all the PD-linked mutations alter the
interactionswithMKKs,JIPsandtheirlinkedkinasecascades
in PD pathology. Our unpublished data show that genetic
or pharmacological suppression of JNK pathway suppressed
PD-likeParkinsonisminLRRK2transgenicﬂies.Inaddition,
LRRK2 may also interact with ERK1/2 MAPK pathway since
theERKinhibitorU0126canrescueLRRK2G2019S-induced
neurite shortening and cytotoxicity in culture cells [112]. A
report also shows that LRRK2 may interact with oxidative
stress via ERK phosphorylation [94]. Like RIPK1, LRRK2
interacts with FADD to induce death signaling resulting
in caspase activation and apoptosis [93]. Taken together,
these studies suggest that LRRK2 may act as an upstream
kinaseandinteractwithmultiplecellularstressandcelldeath
signaling pathways.
LRRK2 also associated with other PD-linked proteins.
Co-immunoprecipitation studies have shown that LRRK2
associates with the PD-associated protein parkin [79]
although there is a conﬂicting report using a diﬀerent
tagged LRRK2 construct that can not co-IP with parkin
[110]. But further Drosophila studies including our own
observations show that parkin suppressed LRRK2-induced
PD-like phenotypes, suggesting that parkin is associated
with LRRK2 in vivo [117, 118]. Although LRRK2 cannot
directly bind α-synuclein, DJ-1, or pink-1, there are genetic
interactions between LRRK2 and these genes in Drosophila
[79, 118], C. elegans [119, 120], cell cultures [121]a n d
m o u s em o d e l s[ 122]. This is illustrated by studies showing
that expression of mutant LRRK2 promotes α-synuclein
pathology in mice [103]. Since LRRK2 interacts with 14-3-
3 proteins [64–66], which also interact with α-synuclein and
negatively regulate cell death pathways, it is suggested that
LRRK2 may indirectly interact with α-synculein via other
proteins such as 14-3-3 to converge in PD. Given LRRK2
is a large and complex protein, further identiﬁcation and
characterization of LRRK2 interaction partners and their
linked pathways is necessary to decipher the main functional
roles of LRRK2 in PD pathogenesis.
4. AnimalModels for LRRK2-Linked
Parkinsonism(Table 3)
4.1. LRRK2 Drosophila Model. Drosophila melanogaster is
an excellent model organism for studying pathogenesis and
therapeutics of neuronal degenerative diseases [123, 124].8 Parkinson’s Disease
Use of the ﬂy system has led to the unveiling of molecular
and cellular pathophysiology of neurodegeneration, and has
potential in discovering novel drug targets for long-sought
therapeutics. Fly models have been successfully used to
study the roles of α-synuclein, parkin, pink-1, DJ-1 and
stress factors as well as provide important insights into
disease pathogenesis [125–138]. Approximately 75% of the
disease-related loci in humans have at least one Drosophila
homologue, indicating a high degree of conservation from
ﬂies to human [139]. Adult ﬂy brains have 13 dopaminergic
neuron clusters with more than 1000 neurons that can be
labeled with antityrosine hydroxylase (TH) antibodies, as
illustrated in Figure 1. The ﬂy has one homologue (CG5483)
of human LRRK2. Several groups have generated transgenic
or loss-of-function mutants LRRK2 ﬂy models using UAS-
GAL4 system (Table 3). This system takes advantage of the
ﬁndings that the yeast GAL4 transcription factor binds
very speciﬁcally to an upstream activation sequence (UAS).
LRRK2 transgenes can be expressed either in various tissues
or in a small group of speciﬁc cells under the control of the
given promoter (promoter-GAL4).
Loss-of-function mutant studies indicate that CG5483
protein is critical for the integrity of ﬂy DA neurons [53]
and control of synaptic overgrowth [140]. Drosophila lines
expressing either ﬂy LRRK (dLRRK)[ 53, 71]o rh u m a n
LRRK2 [117, 118, 141]r e s e m b l es o m ef e a t u r e so fL R R K 2 -
linked Parkinsonism. Inactivation of dLRRK kinase activity
is not essential for ﬂy development [142]. Although the
neurochemical and behavioral phenotypes of these LRRK2
ﬂies diﬀer considerably from various groups. Transgenic
expression of Drosophila wild-type LRRK2 homology pro-
tein (CG5483) and a mutation (R1069C) corresponding to
the human “R1441C” mutation does not show any signiﬁ-
cant defects [53]. However, this mutation in the context of
Drosophila CG5483 may not be as pathogenic as the same
R1441C change in the context of the human LRRK2 patients.
Alternatively, the expression level of this mutant allele may
not reach the pathology threshold in the ﬂy. Overexpressing
the human wild-type LRRK2 and the most common mutant
form LRRK2-G2019S led to a selective loss of dopaminergic
neurons in the brain, early mortality and locomotor impair-
ment as reported by our group [141]. Moreover, LRRK2-
G2019S increased autophosphorylation activity and caused
a more severe parkinsonism-like phenotype than did wild-
type LRRK2. Treatment with L-DOPA improved the mutant
LRRK2-induced locomotor impairment, but did not prevent
the loss of dopaminergic neurons, similar to what is seen
in LRRK2-linked human PD. In support of this line of
ﬁndings, several groups [117, 118, 141] have shown loss of
dopamine and of dopaminergic neurons accompanied by
behavioral deﬁcits in their LRRK2 ﬂy models. Coexpression
of human parkin in LRRK2 G2019S-expressing ﬂies provides
signiﬁcant protection against DA neurodegeneration that
o c c u r sw i t ha g eo ri nr e s p o n s et or o t e n o n e[ 117]. Imai et
al. reported that both human LRRK2 and the Drosophila
orthologue of LRRK2 phosphorylate eukaryotic initiation
factor 4E-(eIF4E-) binding protein (4E-BP), a negative
regulator of eIF4E-mediated protein translation is a key
mediator of various stress responses and suggest that 4E-BP
may be a potential LRRK2 substrate [71]. Tain et al. have
shown that loss of the Drosophila LRRK2 homolog activated
4E-BP and is able to suppress Pink-1 and parkin pathology
[153]. Additionally, a recent study reports that LRRK2
interacts with 4E-BP at the postsynapse, whereas LRRK2
phosphorylates and negatively regulates the microtubule
(MT-) binding protein Futsch at the presynapse [140].
LRRK2 also interacts with the microRNA (miRNA)
pathway to regulate protein synthesis. Drosophila e2f1 and
dp messenger RNAs are translationally repressed by let-7
and miR-184, respectively. Pathogenic LRRK2 antagonizes
these miRNAs, leading to the overproduction of E2F1/DP,
previously implicated in cell cycle and survival control and
shown here to be critical for LRRK2 pathogenesis. LRRK2
associates with Drosophila Argonaute-1 (dAgo1) or human
Argonaute-2(hAgo2)oftheRNA-inducedsilencingcomplex
(RISC). In aged ﬂy brain, dAgo1 protein level is negatively
regulated by LRRK2. Furthermore, pathogenic LRRK2 pro-
motestheassociationofphospho-4E-BP1withhAgo2.These
studies suggest that deregulated synthesis of E2F1/DP caused
by the miRNA pathway impairment is a key event in LRRK2
pathogenesis [154]. With an outstanding battery of genetic
tools for gene manipulation as well as the ability to carry
out large-scale genetic screens inexpensively and rapidly for
mutations aﬀecting the disease process, the LRRK2 ﬂy model
provides a powerful tool to screen for LRRK2 interaction
partners and LRRK2 substrates. Furthermore, the LRRK2
ﬂy model can be used to conduct preclinical therapeutic
screens to prevent neuronal loss and to rescue locomotor
d y s f u n c t i o ni nP D .
4.2. LRRK2 Caenorhabditis Elegan Models. LRK-1 is the
Caenorhabditis elegans ortholog of human LRRK2, and
transgenic as well as deletion mutants have been created in
the worm [73, 119, 120, 143, 144, 155]. In LRK-1 deletion
mutants, synaptic vesicle proteins mislocalize to both presy-
naptic and dendritic endings in neurons, suggesting that
LRK-1 is involved in determining polarized sorting of synap-
tic vesicle proteins to axons by excluding these proteins from
the dendrite-speciﬁc transport machinery in the Golgi [145].
In Wolozin et al.’s earlier studies, overexpression of wild-type
and LRRK2 (G2019S) in C. elegans was protective against
rotenone toxicity, whereas knockdown of endogenous LRK-
1 by RNAi promoted toxicity, suggesting a role for LRRK2 in
mitochondrial regulation [144] .I nc o n t r a s t ,ar e c e n ts t u d y
shows that the transgenic C. elegans overexpressing human
LRRK2 wild type, R1441C and G2019S in dopaminergic
(DA) neurons causes age-dependent DA neurodegeneration,
behavioral deﬁcits, and locomotor dysfunction that are
accompanied by a reduction of dopamine levels in vivo.
In comparison, R1441C and G2019S mutants cause more
severe phenotypes than the wild-type protein. Interestingly,
treatment with exogenous dopamine rescues the LRRK2-
induced behavioral and locomotor phenotypes. In contrast,
expression of the GTP-binding defective mutant, K1347A,
or knockout of the C. elegans LRRK2 homolog, LRK-1,
prevents the LRRK2-induced neurodegeneration and behav-
ioral abnormalities. These results provide strong support forParkinson’s Disease 9
Table 3: LRRK2 animal models.
Drosophila model
Transgene Loss of TH positive
neurons Lewy body Motor
deﬁcits
Suitability for testing
disease modifying therapy Reference
LRRKWT,
LRRKR1069C (R1441C)
LRRKP1, LRRKex1 (loss-of-function line)
ND ND + ND [53]
dLRRK(−/−), dLRRK(+/−),
dLRRK RNAi, dLRRK Tg,
R1069G(R1441G), Y1383C(Y1699C),
I1915T(I2020T)
+N D + N D [ 71]
dLRRKe03680, dLRRK-WT,
dLRRK- I1915T, dLRRKdf ND ND + ND [140]
WT, G2019S, Y1699C,
G2385R +N D + + [ 117]
hLRRK2(WT), hLRRK2(I1122V),
hLRRK2(Y1699C), hLRRK2(I2020T) +N D + + [ 118]
WT, G2019S + ND + ND [141]
dLRRK-WT, dLRRK-mutant(e03680) + ND ND Maybe [142]
Caenorhabditis elegans model
LRRK2+: lrk-1(km17),
LRRK2+: lrk-1(km41),
G2019S+: lrk-1(km41)
LRRK2+: lin-15(765ts)
R1441C+: lin-15(765ts)
G2019S+: lin-15(765ts)
K1347A+: lin-15(765ts)
+N D + N D [ 119]
wlzIs2(WT), km4, N2(WT) ND ND ND ND [73]( I n t e r a c t
with MKK6)
wlzIs1(WT), wlzIs2(WT),
wlzIs3(G2019S), wlzIs4(G2019S),
wlzIs5(R1441C), wlzIs6(KD),
wlzIs7(R1441C/KD),
wlzIs2:wlzIs4(LRRK2/DAT::GFP)
+N D N D + [ 143]
LGI, lrk-1(tm1898, km41);
LGII, pink-1(tm1779); LGX,
lqIs4 (ceh-10::gfp, lin-15(n765)), N2
ND ND ND ND [120]( I n t e r a c t
with PINK1)
N2(WT), N2(G2019S) ND ND ND + [144]
LRK-1-K1726A(hLRRK2-I2020T)
LRK-1-I1877T)(hLRRK2-I2020T) ND ND ND ND
[145]
(trans-Golgi
network)
Rodent model
BAC(WT) + −− ND [27]
BAC(G2019S) ND ND + ND [146]
LRRK2R1441G BAC + − +M a y b e [ 147]
R1441C KI ND ND +(AMPH-
induced)
− [148]
BAC(WT)
BAC(G2019S) +N D N D M a y b e [ 149]
BAC(WT)
BAC(G2019S) +N D + N D [ 150]
WT, A53T, G2019S, KD,
A53T/LRRK2WT, A53T/LRRK2G2019S,
LRRK2−/−
ND + ND ND [103]
LRRK2 null − ND ND ND [151]
LRRK2−/− − +(Kidney) ND ND [122]
HSV-WTHSV-G2019SHSV-
G2019S/D1994A +N D N D + [ 152]
LRRK2 conditional G2019S ND ND ND Maybe [81] (Hsp90 and
LRRK2 stability)
WT: wild type; ND: not determined; GFP: Green ﬂuorescent protein; KI, knocking in.10 Parkinson’s Disease
the critical role of GTPase/kinase activity in LRRK2-linked
pathologies [119].
4.3. Zebraﬁsh Model. Zebraﬁsh have a homolog of human
LRRK2 (XM 682700). The blockage of zebraﬁsh LRRK2
(zLRRK2) protein by morpholinos caused embryonic lethal-
ity and severe developmental defects such as growth retar-
dation and loss of neurons. In contrast, the deletion of the
WD40 domain of zLRRK2by morpholinos targeting splicing
did not induce severe embryonic developmental defects;
rather it caused Parkinsonism-like phenotypes, including
loss of dopaminergic neurons in the diencephalon and
locomotion defects. These neurodegenerative and locomo-
tion defects could be rescued by overexpressing zLRRK2 or
hLRRK2 mRNA [54]. The zLRRK2-ΔWD40 deletion also
caused a signiﬁcant reduction and disorganization of axon
tracts, more prominently in the midbrain. These studies
suggest that zLRRK2 may play an important role in neuronal
development and provide a useful small vertebrate model for
PD research.
4.4. LRRK2 Rodent Models. The LRRK2 protein expressed
in mice shares 86% homology with the human protein
(Genbank: NM-25730). Several groups generated LRRK
transgenic and knockout models but they are not very
robust PD models (Table 3). LRRK2 transgenic mice show
some neurochemical and behavioral abnormalities but lack
selective loss of dopaminergic neurons in substantia nigra
[95, 103, 146–150]. Knockout of LRRK2 in mice also
lack the obvious abnormality in DA neurons in brains
[122, 151].
Conditional expression of LRRK2 WT and LRRK2
G2019S failed to exhibit neurodegeneration of DA neurons,
but LRRK2 was expressed at low levels in DA neurons due
to the use of the calcium/calmodulin dependent protein
kinase II (CamKII) promoter [81, 103]. When the R1441C
mutation is expressed under the control of the endogenous
regulatory elements, by knock in of the R1441C mutation,
there is no degeneration of DA neurons, but they show
reductions in amphetamine-(AMPH-) induced locomotor
activity [148]. Bacterial artiﬁcial chromosome (BAC) trans-
genic mice expressing LRRK2 WT, LRRK2 R1441G, LRRK2
G2019S have some evidence of neurodegeneration [147,
150], which is demonstrated by measuring the dopamine
content after pharmacologically blocking the dopamine
uptake. Li et al. report LRRK2R 1441G BAC transgenic mice
display hyperphosphorylation of tau and motor deﬁcits.
Two groups recently report that G2019S Lrrk2 BAC mice
display abnormal dopamine neurotransmission as evident
by a decrease in extracellular dopamine levels [149, 150].
However, Li et al. shows that the wild-type LRRK2 BAC mice
revealed increases in dopamine release thereby contributing
to hyperactivity phenotypes, while Melrose et al. shows wild-
type LRRK2 mice also decrease dopamine levels but a bit
less than G2019S-LRRK2 BAC mice. Moreover, they later
also show that G2019S-LRRK2 BAC mice display changes in
localization and increased phosphorylation of microtubule
binding protein tau, suggesting that LRRK2 may impact tau
processing [150].
Mutations in α-synuclein and Leucine-rich repeat kinase
2 (LRRK2) are linked to autosomal dominant forms of
Parkinson’s disease (PD). Recently, Lin et al. shows that there
is a potential pathophysiological interplay between these two
PD-related genes by generating a double transgenic mouse
model coexpressing both human α-synuclein and LRRK2
genes [103]. Overexpression of LRRK2 alone did not cause
neurodegeneration but the presence of excess LRRK2 greatly
accelerated the progression of neuropathological abnormal-
ities developed in PD-related A53T α-synuclein transgenic
mice.Moreover,LRRK2promotedtheabnormalaggregation
and somatic accumulation of α-synuclein in A53T mice,
which likely results from the impairment of microtubule
dynamics,Golgiorganization,andtheubiquitin-proteasome
pathway. Conversely, genetic ablation of LRRK2 preserved
the Golgi structure and suppressed the aggregation and
somatic accumulation of α-synuclein, thereby delaying the
progression of neuropathology in A53T mice. These ﬁndings
suggest that overexpression of LRRK2 enhances α-synuclein-
mediated cytotoxicity [103]. Currently, there are no mouse
models that overexpression mutant LRRK2 in parkin, pink-1
or DJ-1 knockout backgrounds.
LRRK2 knockout (KO) mice [151] are viable, have no
major abnormalities and live to adulthood. Moreover, there
is no signiﬁcant diﬀerence in the susceptibility of LRRK2
KO and wild type mice to MPTP suggesting that LRRK2
may play a minor role in the development and the survival
of DA neurons. Alternatively, the roles of LRRK2 may be
compensated by LRRK1 since LRRK1 shares high homology
with LRRK2 and is expressed in the brains. However, a
recent study shows that there is an age-dependent kidney
abnormality in LRRK2 KO mice. The kidneys of these
mice, develop striking accumulation and aggregation of α-
synuclein and ubiquitinated proteins, and may be involved
in the autophagy-lysosomal defects [122]. The kidneys
also display apoptotic cell death, oxidative damage and
inﬂammatory response, suggesting that LRRK2 may play an
important peripheral role during aging at least in kidney.
Most of the current LRRK2 transgenic mice have abnor-
malities in the nigrostriatal system, such as stimulated DA
neurotransmission, decrease dopamine levels, or behavioral
deﬁcits, which probably represent some of the earliest
neuronal dysfunction that is set in motion by pathogenic
LRRK2 mutations. Reasons are not clear why mouse LRRK2
transgenic models do not exhibit more substantial pathology
and why LRRK2 KO mice do not display abnormality in
nigrostriatal system. It may relate to the fact that LRRK2
mutations in humans are only partially penetrant and that
there may need to be other genetic and/or environmental
hits that are required for degeneration of DA neurons.
The BAC and knock in models express mutant LRRK2
during development and thus there may be compensatory
mechanisms in the mouse that prevent loss of DA neurons
by LRRK1 or other genes with the similar functions. Current
mouse LRRK2 models can be used for early mechanism
studies of LRRK2 but are less than ideal to test the
neuronprotection therapies. The rodent models need to
be improved by combining other PD risk factors, or by
other approaches to express LRRK2 in the nigrostriatalParkinson’s Disease 11
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Figure 3: Potential pathways associated with LRRK2 in PD.
system. A recent promising mouse model is using AAV-
mediated expression of mutant LRRK2 in middle brain
causesremarkabledopaminergicneurondegeneration[152],
which can be potentially used to test protective therapeutics
of LRRK2-linked diseases.
5. Conclusion Remarks
In summary, the current ﬁndings in LRRK2 indicate that
kinase activity and GTPase domain activity are the key com-
ponentsofLRRK2functionsandareassociatedwithLRRK2-
induced neuronal degeneration. Mutations within LRRK2
may potentially perturb protein conformation or protein-
protein interactions with accessory proteins necessary for
kinase and GTPase domain activity. It is important to note,
however, that the increase in kinase activity seen with PD-
associated mutations of LRRK2 must be interpreted with
caution until these observations are conﬁrmed with phys-
iologically relevant substrates. Nevertheless, these current
ﬁndings in LRRK2 kinase and GTPase are consistent with a
model in which LRRK2 cycles between an active and an inac-
tive conformation potentially integrating multiple signaling
pathways and subsequently lead to protein aggregation and
neurodegeneration. LRRK2 may also serve as a scaﬀold
protein to recruit other signaling molecules through its
protein-protein interaction domains. Thus, LRRK2 kinase,
GTPasedomain and scaﬀoldactivities may functiontogether
with other PD-related players to elicit disease pathology as
depicted in Figure 3.
In addition, mutant LRRK2 may directly or indirectly
interact with environmental factors and other genetic PD
causes to converge on the pathways that induce protein
aggregation and neuronal death. These interactions may
occur at various levels, such as altering LRRK2 GTP-binding,
GTPase and/or kinase activity, modulating LRRK2 kinase
substrates, or inﬂuencing the function of LRRK2 interaction
partners among others yet to be identiﬁed. Thus, identifying
the putative LRRK2-interacting proteins, physiological sub-
stratesofLRRK2kinase,regulatorsanddownstreameﬀectors
ofLRRK2GTPase,aswellasestablishinghowmutationslead
tothefamilialandsporadicformsofPDthroughinteractions
between genetic factors and environmental toxins will likely
provide crucial insights into the pathways involved in PD
pathogenesis. Such investigations will facilitate the develop-
ment of LRRK2 cell and animal models as well as enable the
formulation of novel pharmacological interventions for the
treatment of PD. The current ﬁndings in LRRK2 are begin-
ning to pave the way for better-designed therapeutic options.
The discovery of chemical inhibitors of LRRK2 kinase and
GTPase domain activities may likely involve optimizing
strategies that prevent dopaminergic neuron degeneration
and to treat LRRK2-linked PD. Recently, several groups
already report some potential LRRK2 kinase inhibitors in
preventing neuronal death [85, 95, 121]. With more research
into the genetics and biochemistry of LRRK2 and more
LRRK2 animal models available, identifying LRRK2 kinase
and GTPase domain inhibitors might lead us to eﬀective new
therapeutic approaches for the treatment of PD.
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